ReviewHematology, transfusion and cell therapy
Warm autoimmune hemolytic anemia in adults in Latin America: A scoping review.
Review in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune hemolytic anemia is a rare disorder characterized by the autoimmune-mediated destruction of red blood cells. The condition is classified into subtypes based on the thermal reactivity of the autoantibodies, with warm autoimmune hemolytic anemia representing the most common form in adults. This review aimed to summarize the clinical evidence regarding warm autoimmune hemolytic anemia generated in adult patients within the Latin American region.
methodsA literature search was conducted in Embase, Medline, Lilacs, Cochrane Library, Epistemonikos, and Value in Health in April 2023. Gray literature was also consulted. Records were eligible for inclusion if they presented data on the epidemiology, diagnosis, treatment, or healthcare resource utilization among adult warm autoimmune hemolytic anemia patients in Latin American countries. Clinical practice guidelines on the condition issued in Latin American were also eligible.
resultsNine records were included: seven retrospective studies (six single-center), one national clinical guidelines (Mexico), and one therapeutic protocol (Brazil). Corticosteroids are the cornerstone of first-line treatment, reported in 97.7 % of 354 patients enrolled in the studies, primarily as monotherapy (91 %). While response rates were high (69-84 %), a considerable proportion of patients (15-40 %) required second-line therapies. The use of splenectomy varied widely between studies, from being the preferred second-line option to not being performed in any patient. Access barriers contribute to a limited use of rituximab.
conclusionCompared to other hemolytic disorders, warm autoimmune hemolytic anemia studies are lacking in Latin American and consist primarily of single-center, retrospective case series. Further research is warranted to understand management strategies in refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.